|
Market Closed -
NSE India S.E.
07:05:08 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 2,325.70 INR | -2.28% |
|
-5.07% | +14.27% |
| 09-11 | Glenmark Pharmaceuticals Limited Proposes Dividend for the Year Ended 31 March 2026 | CI |
| 09-07 | Acucort wins trademark protection for Zeqmelit in Ukraine | FW |
Projected Income Statement: Glenmark Pharmaceuticals Limited
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 123,409 | 129,901 | 118,131 | 133,217 | 169,825 | 167,925 | 187,122 | 208,096 |
| Change | - | 5.26% | -9.06% | 12.77% | 27.48% | -1.12% | 11.43% | 11.21% |
| EBITDA 1 | 23,203 | 22,784 | 11,953 | 23,514 | 45,724 | 36,102 | 42,870 | 47,723 |
| Change | - | -1.81% | -47.54% | 96.71% | 94.46% | -21.04% | 18.75% | 11.32% |
| EBIT 1 | 18,336 | 16,671 | 6,134 | 18,654 | 39,989 | 29,950 | 35,801 | 38,801 |
| Change | - | -9.08% | -63.2% | 204.09% | 114.38% | -25.11% | 19.54% | 8.38% |
| Interest Paid 1 | -2,981 | -3,496 | -5,160 | -2,071 | -2,087 | -1,160 | -949.1 | -390.2 |
| Earnings before Tax (EBT) 1 | 14,412 | 8,685 | 365 | 13,992 | 19,847 | 30,460 | 37,082 | 41,752 |
| Change | - | -39.74% | -95.8% | 3,733.97% | 41.85% | 53.47% | 21.74% | 12.59% |
| Net income 1 | 9,936 | 2,972 | -15,017 | 10,471 | 13,619 | 23,110 | 27,707 | 29,641 |
| Change | - | -70.08% | -605.2% | 169.73% | 30.06% | 69.7% | 19.89% | 6.98% |
| Announcement Date | 5/27/22 | 5/19/23 | 5/24/24 | 5/23/25 | 5/29/26 | - | - | - |
Forecast Balance Sheet: Glenmark Pharmaceuticals Limited
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 25,505 | 31,575 | -6,677 | 7,674 | -5,827 | -36,491 | -48,003 | -58,091 |
| Change | - | 23.8% | -121.15% | 214.93% | -175.93% | -526.21% | -31.55% | -21.02% |
| Announcement Date | 5/27/22 | 5/19/23 | 5/24/24 | 5/23/25 | 5/29/26 | - | - | - |
Cash Flow Forecast: Glenmark Pharmaceuticals Limited
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| CAPEX 1 | 7,901 | 6,078 | 8,984 | 7,496 | 13,577 | 9,116 | 9,633 | 12,602 |
| Change | - | -23.08% | 47.82% | -16.56% | 81.13% | -32.86% | 5.67% | 30.83% |
| Free Cash Flow (FCF) 1 | 3,185 | 176.3 | -11,638 | -15,772 | 20,873 | 16,643 | 18,956 | 21,620 |
| Change | - | -94.47% | -6,701.75% | -35.52% | 232.35% | -20.27% | 13.9% | 14.05% |
| Announcement Date | 5/27/22 | 5/19/23 | 5/24/24 | 5/23/25 | 5/29/26 | - | - | - |
Forecast Financial Ratios: Glenmark Pharmaceuticals Limited
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | 18.8% | 17.54% | 10.12% | 17.65% | 26.92% | 21.5% | 22.91% | 22.93% |
| EBIT Margin (%) | 14.86% | 12.83% | 5.19% | 14% | 23.55% | 17.84% | 19.13% | 18.65% |
| EBT Margin (%) | 11.68% | 6.69% | 0.31% | 10.5% | 11.69% | 18.14% | 19.82% | 20.06% |
| Net margin (%) | 8.05% | 2.29% | -12.71% | 7.86% | 8.02% | 13.76% | 14.81% | 14.24% |
| FCF margin (%) | 2.58% | 0.14% | -9.85% | -11.84% | 12.29% | 9.91% | 10.13% | 10.39% |
| FCF / Net Income (%) | 32.06% | 5.93% | 77.5% | -150.62% | 153.27% | 72.01% | 68.42% | 72.94% |
Profitability | ||||||||
| ROA | 6.08% | - | - | - | - | - | - | - |
| ROE | 12.3% | 6.79% | -11.52% | 16.76% | 14.07% | 19.47% | 19.63% | 18.41% |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | 1.1x | 1.39x | - | 0.33x | - | - | - | - |
| Debt / Free cash flow | 8.01x | 179.11x | - | -0.49x | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | 6.4% | 4.68% | 7.6% | 5.63% | 7.99% | 5.43% | 5.15% | 6.06% |
| CAPEX / EBITDA (%) | 34.05% | 26.68% | 75.16% | 31.88% | 29.69% | 25.25% | 22.47% | 26.41% |
| CAPEX / FCF (%) | 248.05% | 3,447.52% | -77.19% | -47.53% | 65.05% | 54.77% | 50.81% | 58.29% |
Items per share | ||||||||
| Cash flow per share 1 | 39.29 | 22.15 | -9.41 | -29.33 | 122.1 | 63.92 | 102.5 | 104.9 |
| Change | - | -43.61% | -142.47% | -211.66% | 516.25% | -47.64% | 60.39% | 2.28% |
| Dividend per Share 1 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 3.82 | 4.02 | 3.75 |
| Change | - | 0% | 0% | 0% | 0% | 52.8% | 5.24% | -6.72% |
| Book Value Per Share 1 | 322 | 335.8 | 278.1 | 313.6 | 372.5 | 448 | 540 | 636.9 |
| Change | - | 4.26% | -17.17% | 12.76% | 18.78% | 20.26% | 20.54% | 17.95% |
| EPS 1 | 33.4 | 10.53 | -53.22 | 37.11 | 48.24 | 82.22 | 98.93 | 108.8 |
| Change | - | -68.47% | -605.41% | 169.73% | 29.99% | 70.44% | 20.33% | 9.94% |
| Nbr of stocks (in thousands) | 282,168 | 282,168 | 282,188 | 282,188 | 282,201 | 282,201 | 282,201 | 282,201 |
| Announcement Date | 5/27/22 | 5/19/23 | 5/24/24 | 5/23/25 | 5/29/26 | - | - | - |
| 2027 * | 2028 * | |
|---|---|---|
| P/E | 28.3x | 23.5x |
| PBR | 5.19x | 4.31x |
| EV / Sales | 3.69x | 3.25x |
| Yield | 0.16% | 0.17% |
EPS & Dividend
Y-o-Y evolution of P/E
Year-on-year evolution of the Yield
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLENMARK Stock
- Financials Glenmark Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
